ID: ALA1819615

Max Phase: Preclinical

Molecular Formula: C26H25FN2O5

Molecular Weight: 464.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(OC[C@@H]2CN(C)c3ccccc3O2)ccc1C(=O)Nc1cc(CC(=O)O)ccc1F

Standard InChI:  InChI=1S/C26H25FN2O5/c1-16-11-18(33-15-19-14-29(2)23-5-3-4-6-24(23)34-19)8-9-20(16)26(32)28-22-12-17(13-25(30)31)7-10-21(22)27/h3-12,19H,13-15H2,1-2H3,(H,28,32)(H,30,31)/t19-/m0/s1

Standard InChI Key:  VOARYSGSCSJFJB-IBGZPJMESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 464.49

Molecular Weight (Monoisotopic): 464.1748

AlogP: 4.29

#Rotatable Bonds: 7

Polar Surface Area: 88.10

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.55

CX Basic pKa: 1.55

CX LogP: 4.84

CX LogD: 1.48

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.54

Np Likeness Score: -1.01

References

1. Iwahashi M, Takahashi E, Tanaka M, Matsunaga Y, Okada Y, Matsumoto R, Nambu F, Nakai H, Toda M..  (2011)  Design and synthesis of new prostaglandin D₂ receptor antagonists.,  19  (18): [PMID:21885288] [10.1016/j.bmc.2011.08.007]

2. Iwahashi M, Naganawa A, Kinoshita A, Shimabukuro A, Nishiyama T, Ogawa S, Matsunaga Y, Tsukamoto K, Okada Y, Matsumoto R, Nambu F, Oumi R, Odagaki Y, Katagi J, Yano K, Tani K, Nakai H, Toda M..  (2011)  Discovery of new orally active prostaglandin D2 receptor antagonists.,  19  (22): [PMID:21982795] [10.1016/j.bmc.2011.08.065]

Source

Source(1):

• Scientific Literature